The global market for Indolent Systemic Mastocytosis Treatment was valued at US$ 486 million in the year 2024 and is projected to reach a revised size of US$ 706 million by 2031, growing at a CAGR of 5.7% during the forecast period.

Indolent Systemic Mastocytosis Treatment Market

Indolent Systemic Mastocytosis (ISM) treatment focuses on managing symptoms and improving quality of life, as the disease typically progresses slowly and has a favorable prognosis. Treatment does not aim to cure but to control symptoms caused by mast cell mediator release, such as flushing, anaphylaxis, gastrointestinal discomfort, and skin lesions. Common therapies include antihistamines (H1 and H2 blockers), leukotriene antagonists, mast cell stabilizers (e.g., cromolyn sodium), and epinephrine for emergency reactions. In some cases, tyrosine kinase inhibitors may be considered if symptoms are refractory.

North American market for Indolent Systemic Mastocytosis Treatment is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Indolent Systemic Mastocytosis Treatment is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global market for Indolent Systemic Mastocytosis Treatment in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Indolent Systemic Mastocytosis Treatment include Blueprint Medicines Corporation, Allakos Inc., AstraZeneca, Pfizer Inc., Viatrics, Teva Pharmaceuticals, Novartis AG, Merck KGaA, GSK Plc., Deciphera Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Indolent Systemic Mastocytosis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Indolent Systemic Mastocytosis Treatment.

The Indolent Systemic Mastocytosis Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Indolent Systemic Mastocytosis Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Indolent Systemic Mastocytosis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Indolent Systemic Mastocytosis Treatment Market Report

Report Metric	Details
Report Name	Indolent Systemic Mastocytosis Treatment Market
Accounted market size in year	US$ 486 million
Forecasted market size in 2031	US$ 706 million
CAGR	5.7%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Multikinase Inhibitor Antihistamines Other
Segment by Application	Hospital Retail Pharmacy Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Blueprint Medicines Corporation, Allakos Inc., AstraZeneca, Pfizer Inc., Viatrics, Teva Pharmaceuticals, Novartis AG, Merck KGaA, GSK Plc., Deciphera Pharmaceuticals, Sanofi Aventis, Eli Lilly & Company
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Indolent Systemic Mastocytosis Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Indolent Systemic Mastocytosis Treatment Market growing?

Ans: The Indolent Systemic Mastocytosis Treatment Market witnessing a CAGR of 5.7% during the forecast period 2025-2031.

What is the Indolent Systemic Mastocytosis Treatment Market size in 2031?

Ans: The Indolent Systemic Mastocytosis Treatment Market size in 2031 will be US$ 706 million.

Who are the main players in the Indolent Systemic Mastocytosis Treatment Market report?

Ans: The main players in the Indolent Systemic Mastocytosis Treatment Market are Blueprint Medicines Corporation, Allakos Inc., AstraZeneca, Pfizer Inc., Viatrics, Teva Pharmaceuticals, Novartis AG, Merck KGaA, GSK Plc., Deciphera Pharmaceuticals, Sanofi Aventis, Eli Lilly & Company

What are the Application segmentation covered in the Indolent Systemic Mastocytosis Treatment Market report?

Ans: The Applications covered in the Indolent Systemic Mastocytosis Treatment Market report are Hospital, Retail Pharmacy, Others

What are the Type segmentation covered in the Indolent Systemic Mastocytosis Treatment Market report?

Ans: The Types covered in the Indolent Systemic Mastocytosis Treatment Market report are Multikinase Inhibitor, Antihistamines, Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Indolent Systemic Mastocytosis Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Multikinase Inhibitor

1.2.3 Antihistamines

1.2.4 Other

1.3 Market by Application

1.3.1 Global Indolent Systemic Mastocytosis Treatment Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Retail Pharmacy

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Indolent Systemic Mastocytosis Treatment Market Perspective (2020-2031)

2.2 Global Indolent Systemic Mastocytosis Treatment Growth Trends by Region

2.2.1 Global Indolent Systemic Mastocytosis Treatment Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Indolent Systemic Mastocytosis Treatment Historic Market Size by Region (2020-2025)

2.2.3 Indolent Systemic Mastocytosis Treatment Forecasted Market Size by Region (2026-2031)

2.3 Indolent Systemic Mastocytosis Treatment Market Dynamics

2.3.1 Indolent Systemic Mastocytosis Treatment Industry Trends

2.3.2 Indolent Systemic Mastocytosis Treatment Market Drivers

2.3.3 Indolent Systemic Mastocytosis Treatment Market Challenges

2.3.4 Indolent Systemic Mastocytosis Treatment Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Indolent Systemic Mastocytosis Treatment Players by Revenue

3.1.1 Global Top Indolent Systemic Mastocytosis Treatment Players by Revenue (2020-2025)

3.1.2 Global Indolent Systemic Mastocytosis Treatment Revenue Market Share by Players (2020-2025)

3.2 Global Top Indolent Systemic Mastocytosis Treatment Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Indolent Systemic Mastocytosis Treatment Revenue

3.4 Global Indolent Systemic Mastocytosis Treatment Market Concentration Ratio

3.4.1 Global Indolent Systemic Mastocytosis Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Indolent Systemic Mastocytosis Treatment Revenue in 2024

3.5 Global Key Players of Indolent Systemic Mastocytosis Treatment Head office and Area Served

3.6 Global Key Players of Indolent Systemic Mastocytosis Treatment, Product and Application

3.7 Global Key Players of Indolent Systemic Mastocytosis Treatment, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Indolent Systemic Mastocytosis Treatment Breakdown Data by Type

4.1 Global Indolent Systemic Mastocytosis Treatment Historic Market Size by Type (2020-2025)

4.2 Global Indolent Systemic Mastocytosis Treatment Forecasted Market Size by Type (2026-2031)

5 Indolent Systemic Mastocytosis Treatment Breakdown Data by Application

5.1 Global Indolent Systemic Mastocytosis Treatment Historic Market Size by Application (2020-2025)

5.2 Global Indolent Systemic Mastocytosis Treatment Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Indolent Systemic Mastocytosis Treatment Market Size (2020-2031)

6.2 North America Indolent Systemic Mastocytosis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Indolent Systemic Mastocytosis Treatment Market Size by Country (2020-2025)

6.4 North America Indolent Systemic Mastocytosis Treatment Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Indolent Systemic Mastocytosis Treatment Market Size (2020-2031)

7.2 Europe Indolent Systemic Mastocytosis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Indolent Systemic Mastocytosis Treatment Market Size by Country (2020-2025)

7.4 Europe Indolent Systemic Mastocytosis Treatment Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Indolent Systemic Mastocytosis Treatment Market Size (2020-2031)

8.2 Asia-Pacific Indolent Systemic Mastocytosis Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Indolent Systemic Mastocytosis Treatment Market Size by Region (2020-2025)

8.4 Asia-Pacific Indolent Systemic Mastocytosis Treatment Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Indolent Systemic Mastocytosis Treatment Market Size (2020-2031)

9.2 Latin America Indolent Systemic Mastocytosis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Indolent Systemic Mastocytosis Treatment Market Size by Country (2020-2025)

9.4 Latin America Indolent Systemic Mastocytosis Treatment Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Indolent Systemic Mastocytosis Treatment Market Size (2020-2031)

10.2 Middle East & Africa Indolent Systemic Mastocytosis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Indolent Systemic Mastocytosis Treatment Market Size by Country (2020-2025)

10.4 Middle East & Africa Indolent Systemic Mastocytosis Treatment Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Blueprint Medicines Corporation

11.1.1 Blueprint Medicines Corporation Company Details

11.1.2 Blueprint Medicines Corporation Business Overview

11.1.3 Blueprint Medicines Corporation Indolent Systemic Mastocytosis Treatment Introduction

11.1.4 Blueprint Medicines Corporation Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025)

11.1.5 Blueprint Medicines Corporation Recent Development

11.2 Allakos Inc.

11.2.1 Allakos Inc. Company Details

11.2.2 Allakos Inc. Business Overview

11.2.3 Allakos Inc. Indolent Systemic Mastocytosis Treatment Introduction

11.2.4 Allakos Inc. Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025)

11.2.5 Allakos Inc. Recent Development

11.3 AstraZeneca

11.3.1 AstraZeneca Company Details

11.3.2 AstraZeneca Business Overview

11.3.3 AstraZeneca Indolent Systemic Mastocytosis Treatment Introduction

11.3.4 AstraZeneca Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025)

11.3.5 AstraZeneca Recent Development

11.4 Pfizer Inc.

11.4.1 Pfizer Inc. Company Details

11.4.2 Pfizer Inc. Business Overview

11.4.3 Pfizer Inc. Indolent Systemic Mastocytosis Treatment Introduction

11.4.4 Pfizer Inc. Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025)

11.4.5 Pfizer Inc. Recent Development

11.5 Viatrics

11.5.1 Viatrics Company Details

11.5.2 Viatrics Business Overview

11.5.3 Viatrics Indolent Systemic Mastocytosis Treatment Introduction

11.5.4 Viatrics Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025)

11.5.5 Viatrics Recent Development

11.6 Teva Pharmaceuticals

11.6.1 Teva Pharmaceuticals Company Details

11.6.2 Teva Pharmaceuticals Business Overview

11.6.3 Teva Pharmaceuticals Indolent Systemic Mastocytosis Treatment Introduction

11.6.4 Teva Pharmaceuticals Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025)

11.6.5 Teva Pharmaceuticals Recent Development

11.7 Novartis AG

11.7.1 Novartis AG Company Details

11.7.2 Novartis AG Business Overview

11.7.3 Novartis AG Indolent Systemic Mastocytosis Treatment Introduction

11.7.4 Novartis AG Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025)

11.7.5 Novartis AG Recent Development

11.8 Merck KGaA

11.8.1 Merck KGaA Company Details

11.8.2 Merck KGaA Business Overview

11.8.3 Merck KGaA Indolent Systemic Mastocytosis Treatment Introduction

11.8.4 Merck KGaA Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025)

11.8.5 Merck KGaA Recent Development

11.9 GSK Plc.

11.9.1 GSK Plc. Company Details

11.9.2 GSK Plc. Business Overview

11.9.3 GSK Plc. Indolent Systemic Mastocytosis Treatment Introduction

11.9.4 GSK Plc. Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025)

11.9.5 GSK Plc. Recent Development

11.10 Deciphera Pharmaceuticals

11.10.1 Deciphera Pharmaceuticals Company Details

11.10.2 Deciphera Pharmaceuticals Business Overview

11.10.3 Deciphera Pharmaceuticals Indolent Systemic Mastocytosis Treatment Introduction

11.10.4 Deciphera Pharmaceuticals Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025)

11.10.5 Deciphera Pharmaceuticals Recent Development

11.11 Sanofi Aventis

11.11.1 Sanofi Aventis Company Details

11.11.2 Sanofi Aventis Business Overview

11.11.3 Sanofi Aventis Indolent Systemic Mastocytosis Treatment Introduction

11.11.4 Sanofi Aventis Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025)

11.11.5 Sanofi Aventis Recent Development

11.12 Eli Lilly & Company

11.12.1 Eli Lilly & Company Company Details

11.12.2 Eli Lilly & Company Business Overview

11.12.3 Eli Lilly & Company Indolent Systemic Mastocytosis Treatment Introduction

11.12.4 Eli Lilly & Company Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025)

11.12.5 Eli Lilly & Company Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Blueprint Medicines Corporation

Deciphera Pharmaceuticals

Sanofi Aventis

Eli lilly company

Viatrics

List of Tables

Table 1. Global Indolent Systemic Mastocytosis Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Multikinase Inhibitor

Table 3. Key Players of Antihistamines

Table 4. Key Players of Other

Table 5. Global Indolent Systemic Mastocytosis Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Indolent Systemic Mastocytosis Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Indolent Systemic Mastocytosis Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 8. Global Indolent Systemic Mastocytosis Treatment Market Share by Region (2020-2025)

Table 9. Global Indolent Systemic Mastocytosis Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 10. Global Indolent Systemic Mastocytosis Treatment Market Share by Region (2026-2031)

Table 11. Indolent Systemic Mastocytosis Treatment Market Trends

Table 12. Indolent Systemic Mastocytosis Treatment Market Drivers

Table 13. Indolent Systemic Mastocytosis Treatment Market Challenges

Table 14. Indolent Systemic Mastocytosis Treatment Market Restraints

Table 15. Global Indolent Systemic Mastocytosis Treatment Revenue by Players (2020-2025) & (US$ Million)

Table 16. Global Indolent Systemic Mastocytosis Treatment Market Share by Players (2020-2025)

Table 17. Global Top Indolent Systemic Mastocytosis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Indolent Systemic Mastocytosis Treatment as of 2024)

Table 18. Ranking of Global Top Indolent Systemic Mastocytosis Treatment Companies by Revenue (US$ Million) in 2024

Table 19. Global 5 Largest Players Market Share by Indolent Systemic Mastocytosis Treatment Revenue (CR5 and HHI) & (2020-2025)

Table 20. Global Key Players of Indolent Systemic Mastocytosis Treatment, Headquarters and Area Served

Table 21. Global Key Players of Indolent Systemic Mastocytosis Treatment, Product and Application

Table 22. Global Key Players of Indolent Systemic Mastocytosis Treatment, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Indolent Systemic Mastocytosis Treatment Market Size by Type (2020-2025) & (US$ Million)

Table 25. Global Indolent Systemic Mastocytosis Treatment Revenue Market Share by Type (2020-2025)

Table 26. Global Indolent Systemic Mastocytosis Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 27. Global Indolent Systemic Mastocytosis Treatment Revenue Market Share by Type (2026-2031)

Table 28. Global Indolent Systemic Mastocytosis Treatment Market Size by Application (2020-2025) & (US$ Million)

Table 29. Global Indolent Systemic Mastocytosis Treatment Revenue Market Share by Application (2020-2025)

Table 30. Global Indolent Systemic Mastocytosis Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 31. Global Indolent Systemic Mastocytosis Treatment Revenue Market Share by Application (2026-2031)

Table 32. North America Indolent Systemic Mastocytosis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 33. North America Indolent Systemic Mastocytosis Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 34. North America Indolent Systemic Mastocytosis Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 35. Europe Indolent Systemic Mastocytosis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. Europe Indolent Systemic Mastocytosis Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 37. Europe Indolent Systemic Mastocytosis Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 38. Asia-Pacific Indolent Systemic Mastocytosis Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 39. Asia-Pacific Indolent Systemic Mastocytosis Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 40. Asia-Pacific Indolent Systemic Mastocytosis Treatment Market Size by Region (2026-2031) & (US$ Million)

Table 41. Latin America Indolent Systemic Mastocytosis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 42. Latin America Indolent Systemic Mastocytosis Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 43. Latin America Indolent Systemic Mastocytosis Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 44. Middle East & Africa Indolent Systemic Mastocytosis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Middle East & Africa Indolent Systemic Mastocytosis Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 46. Middle East & Africa Indolent Systemic Mastocytosis Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 47. Blueprint Medicines Corporation Company Details

Table 48. Blueprint Medicines Corporation Business Overview

Table 49. Blueprint Medicines Corporation Indolent Systemic Mastocytosis Treatment Product

Table 50. Blueprint Medicines Corporation Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025) & (US$ Million)

Table 51. Blueprint Medicines Corporation Recent Development

Table 52. Allakos Inc. Company Details

Table 53. Allakos Inc. Business Overview

Table 54. Allakos Inc. Indolent Systemic Mastocytosis Treatment Product

Table 55. Allakos Inc. Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025) & (US$ Million)

Table 56. Allakos Inc. Recent Development

Table 57. AstraZeneca Company Details

Table 58. AstraZeneca Business Overview

Table 59. AstraZeneca Indolent Systemic Mastocytosis Treatment Product

Table 60. AstraZeneca Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025) & (US$ Million)

Table 61. AstraZeneca Recent Development

Table 62. Pfizer Inc. Company Details

Table 63. Pfizer Inc. Business Overview

Table 64. Pfizer Inc. Indolent Systemic Mastocytosis Treatment Product

Table 65. Pfizer Inc. Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025) & (US$ Million)

Table 66. Pfizer Inc. Recent Development

Table 67. Viatrics Company Details

Table 68. Viatrics Business Overview

Table 69. Viatrics Indolent Systemic Mastocytosis Treatment Product

Table 70. Viatrics Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025) & (US$ Million)

Table 71. Viatrics Recent Development

Table 72. Teva Pharmaceuticals Company Details

Table 73. Teva Pharmaceuticals Business Overview

Table 74. Teva Pharmaceuticals Indolent Systemic Mastocytosis Treatment Product

Table 75. Teva Pharmaceuticals Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025) & (US$ Million)

Table 76. Teva Pharmaceuticals Recent Development

Table 77. Novartis AG Company Details

Table 78. Novartis AG Business Overview

Table 79. Novartis AG Indolent Systemic Mastocytosis Treatment Product

Table 80. Novartis AG Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025) & (US$ Million)

Table 81. Novartis AG Recent Development

Table 82. Merck KGaA Company Details

Table 83. Merck KGaA Business Overview

Table 84. Merck KGaA Indolent Systemic Mastocytosis Treatment Product

Table 85. Merck KGaA Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025) & (US$ Million)

Table 86. Merck KGaA Recent Development

Table 87. GSK Plc. Company Details

Table 88. GSK Plc. Business Overview

Table 89. GSK Plc. Indolent Systemic Mastocytosis Treatment Product

Table 90. GSK Plc. Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025) & (US$ Million)

Table 91. GSK Plc. Recent Development

Table 92. Deciphera Pharmaceuticals Company Details

Table 93. Deciphera Pharmaceuticals Business Overview

Table 94. Deciphera Pharmaceuticals Indolent Systemic Mastocytosis Treatment Product

Table 95. Deciphera Pharmaceuticals Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025) & (US$ Million)

Table 96. Deciphera Pharmaceuticals Recent Development

Table 97. Sanofi Aventis Company Details

Table 98. Sanofi Aventis Business Overview

Table 99. Sanofi Aventis Indolent Systemic Mastocytosis Treatment Product

Table 100. Sanofi Aventis Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025) & (US$ Million)

Table 101. Sanofi Aventis Recent Development

Table 102. Eli Lilly & Company Company Details

Table 103. Eli Lilly & Company Business Overview

Table 104. Eli Lilly & Company Indolent Systemic Mastocytosis Treatment Product

Table 105. Eli Lilly & Company Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025) & (US$ Million)

Table 106. Eli Lilly & Company Recent Development

Table 107. Research Programs/Design for This Report

Table 108. Key Data Information from Secondary Sources

Table 109. Key Data Information from Primary Sources

Table 110. Authors List of This Report

List of Figures

Figure 1. Indolent Systemic Mastocytosis Treatment Picture

Figure 2. Global Indolent Systemic Mastocytosis Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Indolent Systemic Mastocytosis Treatment Market Share by Type: 2024 VS 2031

Figure 4. Multikinase Inhibitor Features

Figure 5. Antihistamines Features

Figure 6. Other Features

Figure 7. Global Indolent Systemic Mastocytosis Treatment Market Size by Application (2020-2031) & (US$ Million)

Figure 8. Global Indolent Systemic Mastocytosis Treatment Market Share by Application: 2024 VS 2031

Figure 9. Hospital Case Studies

Figure 10. Retail Pharmacy Case Studies

Figure 11. Others Case Studies

Figure 12. Indolent Systemic Mastocytosis Treatment Report Years Considered

Figure 13. Global Indolent Systemic Mastocytosis Treatment Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 14. Global Indolent Systemic Mastocytosis Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global Indolent Systemic Mastocytosis Treatment Market Share by Region: 2024 VS 2031

Figure 16. Global Indolent Systemic Mastocytosis Treatment Market Share by Players in 2024

Figure 17. Global Indolent Systemic Mastocytosis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 18. The Top 10 and 5 Players Market Share by Indolent Systemic Mastocytosis Treatment Revenue in 2024

Figure 19. North America Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. North America Indolent Systemic Mastocytosis Treatment Market Share by Country (2020-2031)

Figure 21. United States Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Canada Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Indolent Systemic Mastocytosis Treatment Market Share by Country (2020-2031)

Figure 25. Germany Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. France Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. U.K. Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Italy Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Russia Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Nordic Countries Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Indolent Systemic Mastocytosis Treatment Market Share by Region (2020-2031)

Figure 33. China Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Japan Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. South Korea Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Southeast Asia Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. India Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Australia Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Indolent Systemic Mastocytosis Treatment Market Share by Country (2020-2031)

Figure 41. Mexico Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Brazil Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Indolent Systemic Mastocytosis Treatment Market Share by Country (2020-2031)

Figure 45. Turkey Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Saudi Arabia Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. UAE Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Blueprint Medicines Corporation Revenue Growth Rate in Indolent Systemic Mastocytosis Treatment Business (2020-2025)

Figure 49. Allakos Inc. Revenue Growth Rate in Indolent Systemic Mastocytosis Treatment Business (2020-2025)

Figure 50. AstraZeneca Revenue Growth Rate in Indolent Systemic Mastocytosis Treatment Business (2020-2025)

Figure 51. Pfizer Inc. Revenue Growth Rate in Indolent Systemic Mastocytosis Treatment Business (2020-2025)

Figure 52. Viatrics Revenue Growth Rate in Indolent Systemic Mastocytosis Treatment Business (2020-2025)

Figure 53. Teva Pharmaceuticals Revenue Growth Rate in Indolent Systemic Mastocytosis Treatment Business (2020-2025)

Figure 54. Novartis AG Revenue Growth Rate in Indolent Systemic Mastocytosis Treatment Business (2020-2025)

Figure 55. Merck KGaA Revenue Growth Rate in Indolent Systemic Mastocytosis Treatment Business (2020-2025)

Figure 56. GSK Plc. Revenue Growth Rate in Indolent Systemic Mastocytosis Treatment Business (2020-2025)

Figure 57. Deciphera Pharmaceuticals Revenue Growth Rate in Indolent Systemic Mastocytosis Treatment Business (2020-2025)

Figure 58. Sanofi Aventis Revenue Growth Rate in Indolent Systemic Mastocytosis Treatment Business (2020-2025)

Figure 59. Eli Lilly & Company Revenue Growth Rate in Indolent Systemic Mastocytosis Treatment Business (2020-2025)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions